But eligibility under IRS rules is the floor, not the ceiling
Such labelling is misleading and deceptive, since none of these products have been tested or authorised by any of the authorities named above
Bak MJ, et.al., Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies
To better understand quality concerns, purity testing, and sourcing risks, explore our analysis of gray-market vs pharmacy-grade peptide sources
doi: 10.1016/j.molmet.2015.07.008 71 MarquesCMegaCGonalvesARodrigues-SantosPTeixeira-LemosETeixeiraFet al
Dehondt H, Marino A, Butruille L, et al